Related Experiment Video
Updated: Jan 7, 2026

Hepatocyte-specific Ablation in Zebrafish to Study Biliary-driven Liver Regeneration
Published on: May 20, 2015
Metronidazole-Induced Encephalopathy in a Patient With Hepatitis B Cirrhosis During Treatment for Intra-abdominal
Ayaka Takahashi1, Masamichi Kimura1, Koji Nishikawa1
1Hepatology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, JPN.
Abstract:
Metronidazole-induced encephalopathy is an uncommon but potentially reversible neurotoxicity characterized by symmetric dentate-nucleus hyperintensities on magnetic resonance imaging. Reduced drug clearance in cirrhosis may lower the toxicity threshold. We report a 72-year-old man with hepatitis B virus-related cirrhosis and hepatocellular carcinoma who underwent right hemicolectomy for bowel perforation due to peritoneal dissemination and subsequently developed recurrent intra-abdominal/retroperitoneal abscesses, with Bacteroides thetaiotaomicron isolated from drainage. Metronidazole 1,500 mg/day was initiated (day 0), briefly substituted with an alternative agent because the patient experienced nausea, and then reintroduced, after which the patient developed dizziness followed by dysarthria and cerebellar ataxia. Brain magnetic resonance imaging on day 63 revealed symmetric T2-weighted and fluid-attenuated inversion recovery hyperintensities in both dentate nuclei consistent with metronidazole-induced encephalopathy. Discontinuation of metronidazole resulted in a gradual clinical improvement, and follow-up magnetic resonance imaging on day 92 showed complete resolution, with a cumulative dose of 76.5 g. This case highlights the occurrence of metronidazole-induced encephalopathy at a sub-100-g exposure in cirrhosis. Thus, new cerebellar signs during therapy should prompt immediate withdrawal, early magnetic resonance imaging, and avoidance of re-exposure.
Insights
Metronidazole-induced encephalopathy, a reversible neurotoxicity, can occur at lower doses in cirrhosis patients. Early recognition of cerebellar signs and drug withdrawal are crucial for recovery.
Area of Science:
- Neurology
- Toxicology
- Gastroenterology
Background:
- Metronidazole-induced encephalopathy (MIE) is a rare, reversible neurotoxicity.
- Cirrhosis may reduce metronidazole clearance, potentially lowering the toxicity threshold.
- Symmetric dentate nucleus hyperintensities on MRI characterize MIE.
Related Concept Videos
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic Drug Excretion: Enterohepatic Cycling
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Factors Influencing Drug Absorption: Disease States and Pharmacology
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

